Sienna Labs – ARCH Venture PartnersSienna Labs –
Development stage company focused on aesthetics and medical dermatology
ARCH Venture Partners leads $34 million Series A financing of Sienna Labs
Sienna Biopharmaceuticals, Inc., a development stage company focused on aesthetics and medical dermatology, today announced that it completed a $34 million Series A financing led by ARCH Venture Partners. Additional investors included Altitude Life Science Ventures, Partner Fund Management, and Venvest Capital, as well as direct investment by several prominent aesthetics and medical dermatology industry luminaries. Sienna Biopharmaceuticals’ mission is to bring to market innovative new products that have the potential to improve patient outcomes and advance the practice of medicine in aesthetics and medical dermatology. The Company brings together the proven leadership and executive team from Kythera Biopharmaceuticals, Inc. (“Kythera”), recently acquired by Allergan, and the backing of several investors who supported the growth and success of Kythera. Leading the Company is Frederick C. Beddingfield III, M.D., Ph.D., as President and CEO, and Keith Leonard, as Executive Chairman.
Sienna Biopharmaceuticals’ lead proprietary technology, Silver Plasmonic Therapy (SPT), has promising applications for acne and permanent hair removal. Clinical trials are already underway and the Company is evaluating additional potential indications.
We are pleased with the opportunity to partner with high-quality investors who share our vision of bringing innovative new products to market in aesthetics and medical dermatology. With this proven team and financing, we have a strong foundation from which we can advance our SPT technology and further our efforts in building a pipeline of early- to late-stage novel assets. All the pieces are in place to create the next great company in aesthetics and medical dermatology.”Frederick C. Beddingfield III, M.D., Ph.DPresident and CEO